{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:26:03Z","timestamp":1788852363751,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejca.2022.05.025","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T04:45:02Z","timestamp":1656132302000},"page":"107-118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Gene expression-based prediction of pazopanib efficacy in sarcoma"],"prefix":"10.1016","volume":"172","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8869-1421","authenticated-orcid":false,"given":"Christoph E.","family":"Heilig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"La\u00dfmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3468-8467","authenticated-orcid":false,"given":"Sadaf S.","family":"Mughal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Mock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Pirmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Teleanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Renner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8960-7719","authenticated-orcid":false,"given":"Carolin","family":"Andresen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno C.","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8183-831X","authenticated-orcid":false,"given":"Bogac","family":"Aybey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5949-8120","authenticated-orcid":false,"given":"Sebastian","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens T.","family":"Siveke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Hamacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Folprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelin","family":"Schr\u00f6ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian H.","family":"Brandts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit","family":"Ahrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hohenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerlinde","family":"Egerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Boerries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L.","family":"Illert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas","family":"von Bubnoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6358-8206","authenticated-orcid":false,"given":"Leonidas","family":"Apostolidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp J.","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Benedikt","family":"Westphalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilko","family":"Weichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Keilholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Klauschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lino","family":"M\u00f6hrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Schulze-Osthoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-3101","authenticated-orcid":false,"given":"Benedikt","family":"Brors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunhild","family":"Mechtersheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3278-4586","authenticated-orcid":false,"given":"Simon","family":"Kreutzfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Heining","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5081-7869","authenticated-orcid":false,"given":"Daniel B.","family":"Lipka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Stenzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Schlenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4536-9306","authenticated-orcid":false,"given":"Peter","family":"Horak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno","family":"Glimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"H\u00fcbschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Fr\u00f6hling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.05.025_bib1","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1016\/j.ejca.2011.08.008","article-title":"Rare cancers are not so rare: the rare cancer burden in Europe","volume":"47","author":"Gatta","year":"2011","journal-title":"Eur J Cancer"},{"issue":"Suppl 4","key":"10.1016\/j.ejca.2022.05.025_bib2","article-title":"Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann Oncol Official J European Soc Medical Oncol"},{"key":"10.1016\/j.ejca.2022.05.025_bib3","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1634\/theoncologist.2017-0383","article-title":"Minimal increase in survival throughout the years in patients with soft tissue sarcoma with synchronous metastases: results of a population-based study","volume":"24","author":"Vos","year":"2019","journal-title":"Oncol"},{"key":"10.1016\/j.ejca.2022.05.025_bib4","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.18_suppl.LBA3","article-title":"ANNOUNCE: a randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS)","volume":"37","author":"Tap","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.05.025_bib5","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","article-title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial","volume":"18","author":"Seddon","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.05.025_bib6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Ian","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.05.025_bib7","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2016.67.6684","article-title":"Picasso III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma","volume":"34","author":"Ryan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.05.025_bib8","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/1535-7163.MCT-07-0193","article-title":"Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity","volume":"6","author":"Kumar","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2022.05.025_bib9","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.biopha.2017.10.058","article-title":"The role of pazopanib on tumour angiogenesis and in the management of cancers: a review","volume":"96","author":"Chellappan","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ejca.2022.05.025_bib10","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1634\/theoncologist.2009-0274","article-title":"(Pre-)Clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor","volume":"15","author":"Hamberg","year":"2010","journal-title":"Oncol"},{"key":"10.1016\/j.ejca.2022.05.025_bib11","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","volume":"27","author":"Sleijfer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.05.025_bib12","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2022.05.025_bib13","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/cncr.29961","article-title":"The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: a Japanese Musculoskeletal Oncology Group (JMOG) study","volume":"122","author":"Nakamura","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2022.05.025_bib14","article-title":"How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers","volume":"35","author":"Tine","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ejca.2022.05.025_bib15","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1586\/era.12.41","article-title":"Pazopanib in the treatment of soft tissue sarcoma","volume":"12","author":"Sch\u00f6ffski","year":"2014","journal-title":"Expert Rev Anticanc"},{"key":"10.1016\/j.ejca.2022.05.025_bib16","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41392-019-0049-6","article-title":"Pazopanib in advanced soft tissue sarcomas","volume":"4","author":"Lee","year":"2019","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ejca.2022.05.025_bib17","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/annonc\/mdt586","article-title":"Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072","volume":"25","author":"Kasper","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.05.025_bib18","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1080\/0284186X.2017.1332779","article-title":"Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study","volume":"56","author":"Gelderblom","year":"2017","journal-title":"Acta Oncol Stock Swed"},{"key":"10.1016\/j.ejca.2022.05.025_bib19","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/annonc\/mdv598","article-title":"TP53 mutational status is predictive of pazopanib response in advanced sarcomas","volume":"27","author":"Koehler","year":"2015","journal-title":"Ann Oncol Official J European Soc Medical Oncol Esmo"},{"key":"10.1016\/j.ejca.2022.05.025_bib20","doi-asserted-by":"crossref","first-page":"x149","DOI":"10.1093\/annonc\/mdx675.001","article-title":"485O A molecular signature predictive of clinical outcome following pazopanib therapy in advanced soft tissue sarcoma","volume":"28","author":"Huang","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.05.025_bib21","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s12885-021-08069-z","article-title":"PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma","volume":"21","author":"Kim","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2022.05.025_bib22","first-page":"6","article-title":"Relationship between PDGFR expression and the response to pazopanib in intimal sarcoma of the pulmonary artery: a case report","volume":"14","author":"Sai","year":"2021","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.ejca.2022.05.025_bib23","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1097\/CORR.0000000000001322","article-title":"Assessment of predictive biomarkers of the response to pazopanib based on an integrative analysis of high-grade soft-tissue sarcomas: analysis of a tumor sample from a responder and patients with other soft-tissue sarcomas","volume":"478","author":"Suehara","year":"2020","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ejca.2022.05.025_bib24","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/ijc.30828","article-title":"Precision oncology based on omics data: the NCT Heidelberg experience","volume":"141","author":"Horak","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2022.05.025_bib25","series-title":"Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers","author":"Horak","year":"2021"},{"key":"10.1016\/j.ejca.2022.05.025_bib26","series-title":"A package for survival analysis in R","author":"Therneau","year":"2021"},{"key":"10.1016\/j.ejca.2022.05.025_bib27","unstructured":"Kassambara A, Kosinski M, Biecek P, Fabian S. survminer: drawing Survival Curves using \u201cggplot2\u201d 2021. https:\/\/cran.r-project.org\/web\/packages\/survminer\/index.html.."},{"key":"10.1016\/j.ejca.2022.05.025_bib28","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1158\/0008-5472.CAN-12-1470","article-title":"Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1\/2 inactivation","volume":"72","author":"Popova","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2022.05.025_bib29","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/bjc.2012.451","article-title":"Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer","volume":"107","author":"Abkevich","year":"2012","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.ejca.2022.05.025_bib30","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/gcc.22918","article-title":"Analysis of mutational signatures with yet another package for signature analysis","volume":"60","author":"H\u00fcbschmann","year":"2021","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.ejca.2022.05.025_bib31","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/s41467-019-09633-9","article-title":"Defective homologous recombination DNA repair as therapeutic target in advanced chordoma","volume":"10","author":"Groschel","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2022.05.025_bib32","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41467-017-02602-0","article-title":"Integrative genomic and transcriptomic analysis of leiomyosarcoma","volume":"9","author":"Chudasama","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2022.05.025_bib33","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","article-title":"Comprehensive and integrated genomic characterization of adult soft tissue sarcomas","volume":"171","author":"Abeshouse","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2022.05.025_bib34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/j.seminoncol.2020.02.009","article-title":"TRK inhibition in soft tissue sarcomas: a comprehensive review","volume":"47","author":"Assi","year":"2020","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2022.05.025_bib35","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.11004","article-title":"Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma","volume":"37","author":"Dickson","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.05.025_bib36","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1470-2045(15)70179-8","article-title":"Nilotinib, imatinib, and GIST therapy","volume":"16","author":"Muro","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.05.025_bib37","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2009.09.022","volume":"46","author":"Sleijfer","year":"2010","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"key":"10.1016\/j.ejca.2022.05.025_bib38","volume":"17","author":"Glabbeke","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2022.05.025_bib39","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1002\/ijc.31286","volume":"142","author":"Lindner","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2022.05.025_bib40","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cell.2020.11.045","article-title":"A modular master regulator landscape controls cancer transcriptional identity","volume":"184","author":"Paull","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2022.05.025_bib41","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.201900445","article-title":"The cancer cell proteome and transcriptome predicts sensitivity to targeted and cytotoxic drugs","volume":"2","author":"Rydenfelt","year":"2019","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.ejca.2022.05.025_bib42","first-page":"1","article-title":"Pazopanib in relapsed osteosarcoma patients: report on 15 cases","volume":"58","author":"Longhi","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2022.05.025_bib43","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1470-2045(16)00075-9","article-title":"Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial","volume":"17","author":"Mir","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.05.025_bib44","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1002\/cncr.30926","article-title":"Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma","volume":"123","author":"Samuels","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2022.05.025_bib45","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1001\/jamadermatol.2017.0187","article-title":"Clinical response to pazopanib in a patient with KDR-mutated metastatic basal cell carcinoma","volume":"153","author":"Knepper","year":"2017","journal-title":"Jama Dermatol"},{"key":"10.1016\/j.ejca.2022.05.025_bib46","doi-asserted-by":"crossref","first-page":"499","DOI":"10.6004\/jnccn.2016.0058","article-title":"Antitumor response of VEGFR2- and VEGFR3-amplified angiosarcoma to pazopanib","volume":"14","author":"Ravi","year":"2016","journal-title":"J Natl Compr Canc Ne"},{"key":"10.1016\/j.ejca.2022.05.025_bib47","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3390\/cancers11030408","article-title":"Overactive IGF1\/insulin receptors and NRASQ61R mutation drive mechanisms of resistance to pazopanib and define rational combination strategies to treat synovial sarcoma","volume":"11","author":"Lanzi","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2022.05.025_bib48","doi-asserted-by":"crossref","first-page":"eaan4368","DOI":"10.1126\/science.aan4368","article-title":"The target landscape of clinical kinase drugs","volume":"358","author":"Klaeger","year":"2017","journal-title":"Science"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922003045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922003045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:37:12Z","timestamp":1760733432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922003045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":48,"alternative-id":["S0959804922003045"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.05.025","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene expression-based prediction of pazopanib efficacy in sarcoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.05.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}